Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Authors
Fizazi, K.Bernard-Tessier, A.
Barthelemy, P.
Utriainen, T.
Roubaud, G.
Flechon, A.
van der Voet, J. C. M.
Mescam, G. G.
Ratta, R.
Jones, R. H.
Parikh, O. A.
Tanner, M. M. E.
Garratt, C.
Nevalaita, L.
Pohjanjousi, P.
Ikonen, T.
Antonarakis, E. S.
Cook, Natalie
Affiliation
Medical Oncology, Institute Gustave Roussy, 94805 - Villejuif/FRIssue Date
2022
Metadata
Show full item recordCitation
Fizazi K, Bernard-Tessier A, Barthelemy P, Utriainen T, Roubaud G, Flechon A, et al. Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients. Annals of Oncology. 2022 Sep;33(7):S1165-S. PubMed PMID: WOS:000866211601621.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1070Additional Links
https://dx.doi.org/10.1016/annonc/annonc1070Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1070